- $21.55bn
- $20.36bn
- $852.53m
Annual balance sheet for Astera Labs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | PRESS |
| Standards: | USG | USG | USG | — |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 163 | 149 | 914 | 1,189 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 10.7 | 8.34 | 38.8 | 83.2 |
| Total Inventory | ||||
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 206 | 186 | 1,013 | 1,362 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 5.29 | 7.58 | 38.6 | 92 |
| Other Long Term Assets | ||||
| Total Assets | 212 | 196 | 1,055 | 1,532 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 40.1 | 35.1 | 86.5 | 133 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 41.9 | 38.9 | 89.7 | 168 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Unrealized Gain / Loss | ||||
| Other Equity | ||||
| Total Equity | 170 | 157 | 965 | 1,364 |
| Total Liabilities & Shareholders' Equity | 212 | 196 | 1,055 | 1,532 |
| Total Common Shares Outstanding |